A 65-year-old woman with COPD GOLD Stage III (FEV₁ 30–49% predicted) presents with 3 moderate exacerbations in the past 12 months. She is currently on tiotropium alone. Which drug should be added to reduce exacerbation risk?

Explanation

## COPD Escalation: LAMA + LABA Combination **Key Point:** In COPD GOLD Stage III with ≥2 moderate exacerbations per year, the next step after LAMA monotherapy is to add a LABA (dual bronchodilator therapy), NOT ICS. This combination is superior to LAMA + ICS for exacerbation reduction in patients without asthma features. ### GOLD 2023 Treatment Algorithm for Exacerbators ```mermaid flowchart TD A[COPD GOLD Stage III]:::outcome --> B{Exacerbation history?}:::decision B -->|0-1 per year| C[LAMA monotherapy]:::action B -->|≥2 per year| D[LAMA + LABA]:::action D --> E{Still exacerbating?}:::decision E -->|Yes| F[Add ICS to LAMA+LABA]:::action E -->|No| G[Continue LAMA+LABA]:::action ``` **High-Yield:** The preferred dual bronchodilator combination for COPD exacerbators is **LAMA + LABA**, not LAMA + ICS. This approach: - Reduces moderate exacerbations by ~30–40% - Improves FEV₁ and symptoms - Avoids unnecessary ICS exposure (which increases pneumonia risk) ### When to Add ICS? ICS is added as a **third agent** (LAMA + LABA + ICS) only if: 1. Patient has ≥2 moderate exacerbations per year despite LAMA + LABA, OR 2. Asthma-COPD overlap is present **Clinical Pearl:** This patient has 3 exacerbations per year on LAMA monotherapy. The next step is LAMA + LABA, not jumping to triple therapy. ICS should be reserved for persistent exacerbators despite dual bronchodilators. **Mnemonic:** COPD exacerbation ladder: - **Stage I–II, 0–1 exacerbations/year:** LAMA or LABA monotherapy - **Stage II–III, ≥2 exacerbations/year:** LAMA + LABA (dual bronchodilators) - **Persistent exacerbations on dual therapy:** Add ICS → LAMA + LABA + ICS (triple therapy) ## Why Other Options Are Wrong - **ICS (fluticasone) alone:** While ICS may be added, it should NOT be the first addition to LAMA. LABA is added first because dual bronchodilators are superior to LAMA + ICS for exacerbation reduction. ICS is added only if exacerbations persist despite LAMA + LABA. - **SABA (salbutamol) as needed:** SABAs provide only acute relief and do not reduce exacerbation frequency. They are used for breakthrough symptoms, not maintenance escalation. - **Roflumilast:** A phosphodiesterase-4 inhibitor used only in severe COPD with chronic bronchitis and frequent exacerbations despite triple therapy. It is not a first-line addition and has significant GI side effects.